Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4868318
Max Phase: Preclinical
Molecular Formula: C102H172N18O39S2
Molecular Weight: 2338.72
Molecule Type: Unknown
Associated Items:
ID: ALA4868318
Max Phase: Preclinical
Molecular Formula: C102H172N18O39S2
Molecular Weight: 2338.72
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccc(-c2cc(NC(=O)CCNC(=O)[C@H](CN)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@@H](CN)C(=O)NCCC(=O)Nc3cc(-c4ccc(C)c(NS(C)(=O)=O)c4)nn4c(C)nnc34)c3nnc(C)n3n2)cc1NS(C)(=O)=O
Standard InChI: InChI=1S/C102H172N18O39S2/c1-81-7-9-85(75-87(81)117-160(5,127)128)89-77-91(99-113-111-83(3)119(99)115-89)107-95(121)11-15-105-101(125)93(79-103)109-97(123)13-17-131-19-21-133-23-25-135-27-29-137-31-33-139-35-37-141-39-41-143-43-45-145-47-49-147-51-53-149-55-57-151-59-61-153-63-65-155-67-69-157-71-73-159-74-72-158-70-68-156-66-64-154-62-60-152-58-56-150-54-52-148-50-48-146-46-44-144-42-40-142-38-36-140-34-32-138-30-28-136-26-24-134-22-20-132-18-14-98(124)110-94(80-104)102(126)106-16-12-96(122)108-92-78-90(116-120-84(4)112-114-100(92)120)86-10-8-82(2)88(76-86)118-161(6,129)130/h7-10,75-78,93-94,117-118H,11-74,79-80,103-104H2,1-6H3,(H,105,125)(H,106,126)(H,107,121)(H,108,122)(H,109,123)(H,110,124)/t93-,94-/m0/s1
Standard InChI Key: VHJWSYBOJKKSRP-QWRUZVEOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2338.72 | Molecular Weight (Monoisotopic): 2337.1470 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Clegg MA, Theodoulou NH, Bamborough P, Chung CW, Craggs PD, Demont EH, Gordon LJ, Liwicki GM, Phillipou A, Tomkinson NCO, Prinjha RK, Humphreys PG.. (2021) Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors., 12 (8.0): [PMID:34413961] [10.1021/acsmedchemlett.1c00294] |
Source(1):